📊 IRD Key Takeaways
Is Opus Genetics, Inc. (IRD) a Good Investment?
Opus Genetics is a pre-commercial biotech company with negative stockholders' equity (-$45.8M) and massive operating losses (-$14.4M on $2.2M revenue). While revenue growth is positive (29.1% YoY) and loss trends are improving YoY, the company remains operationally insolvent with $12.7M annual cash burn and no clear profitability trajectory within visible cash runway (~4.7 years).
Opus Genetics shows meaningful top-line growth, but the quality of that growth is weak because losses remain far larger than revenue and free cash flow is deeply negative. The balance sheet is currently supported by a large cash position and low debt, but without a sharp improvement in operating efficiency or revenue scale, continued cash burn could pressure future funding needs.
Opus Genetics, Inc. Key Strengths (IRD)
- Strong liquidity position with $60M cash providing substantial runway
- Revenue growing at 29.1% YoY with improving loss trends (net loss improved 13.8% YoY, EPS improved 62.8%)
- Low debt burden ($1.2M long-term debt) limiting leverage risk
- Revenue grew 29.1% year over year, indicating commercial or collaboration momentum
- Cash of $45.09M provides a near-term liquidity cushion relative to its size
- Low long-term debt and a 6.43x current ratio reduce immediate balance-sheet stress
IRD Stock Risks: Opus Genetics, Inc. Investment Risks
- Technical insolvency: negative stockholders' equity of -$45.8M indicates liabilities exceed assets
- Massive operating losses with -665.9% operating margin and extreme cash burn of $12.7M annually
- Minimal revenue base ($2.2M) insufficient to justify current cost structure or indicate clear path to profitability
- Operating margin of -271.9% and net margin of -349.3% show the business model is far from self-sustaining
- Operating cash flow and free cash flow of -$35.25M imply a high cash burn rate
- Negative ROE of -323.1% and low equity base increase the risk of future dilution or capital raising
Key Metrics to Watch
- Operating cash flow trend and runway (current 4.7 years at $12.7M burn rate)
- Revenue acceleration and gross margin emergence as commercialization scales
- Operating expense reduction and path to cash flow breakeven timeline
- Quarterly operating cash burn relative to cash balance
- Whether revenue growth begins to materially narrow operating and net losses
Opus Genetics, Inc. (IRD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.13x current ratio provides a solid financial cushion.
IRD Profit Margin, ROE & Profitability Analysis
IRD vs Healthcare Sector: How Opus Genetics, Inc. Compares
How Opus Genetics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Opus Genetics, Inc. Stock Overvalued? IRD Valuation Analysis 2026
Based on fundamental analysis, Opus Genetics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Opus Genetics, Inc. Balance Sheet: IRD Debt, Cash & Liquidity
IRD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Opus Genetics, Inc.'s revenue has grown significantly by 2,310% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.15 indicates the company is currently unprofitable.
IRD Revenue Growth, EPS Growth & YoY Performance
IRD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.2M | -$8.2M | $-0.24 |
| Q3 2025 | $3.1M | -$7.1M | $-0.25 |
| Q2 2025 | $1.1M | -$7.1M | $-0.12 |
| Q1 2025 | $1.7M | -$7.1M | $-0.24 |
| Q3 2024 | $3.9M | -$5.0M | $-0.25 |
| Q2 2024 | $1.1M | -$5.0M | $-0.24 |
| Q1 2024 | $1.7M | -$5.8M | $-0.28 |
| Q3 2023 | N/A | -$4.5M | $-0.22 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Opus Genetics, Inc. Dividends, Buybacks & Capital Allocation
IRD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Opus Genetics, Inc. (CIK: 0001228627)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IRD
What is the AI rating for IRD?
Opus Genetics, Inc. (IRD) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 81% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IRD's key strengths?
Claude: Strong liquidity position with $60M cash providing substantial runway. Revenue growing at 29.1% YoY with improving loss trends (net loss improved 13.8% YoY, EPS improved 62.8%). ChatGPT: Revenue grew 29.1% year over year, indicating commercial or collaboration momentum. Cash of $45.09M provides a near-term liquidity cushion relative to its size.
What are the risks of investing in IRD?
Claude: Technical insolvency: negative stockholders' equity of -$45.8M indicates liabilities exceed assets. Massive operating losses with -665.9% operating margin and extreme cash burn of $12.7M annually. ChatGPT: Operating margin of -271.9% and net margin of -349.3% show the business model is far from self-sustaining. Operating cash flow and free cash flow of -$35.25M imply a high cash burn rate.
What is IRD's revenue and growth?
Opus Genetics, Inc. reported revenue of $2.2M.
Does IRD pay dividends?
Opus Genetics, Inc. does not currently pay dividends.
Where can I find IRD SEC filings?
Official SEC filings for Opus Genetics, Inc. (CIK: 0001228627) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IRD's EPS?
Opus Genetics, Inc. has a diluted EPS of $-0.75.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is IRD's fundamental grade?
Based on our AI fundamental analysis in June 2026, Opus Genetics, Inc. has a C grade with 81% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is IRD stock overvalued or undervalued?
Valuation metrics for IRD: ROE of N/A (sector avg: 15%), net margin of -3,038.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is IRD's AI grade for 2026?
Our dual AI analysis gives Opus Genetics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IRD's free cash flow?
Opus Genetics, Inc.'s operating cash flow is $-12.7M, with capital expenditures of $0.0. FCF margin is -590.0%.
How does IRD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,038.2% (avg: 12%), ROE N/A (avg: 15%), current ratio 7.13 (avg: 2).